AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11916619 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard implantation procedure)
Number of subjects: 186
Study 9785777 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol and fentanyl (group P, n = 107)
Number of subjects: 211
Study 9785777 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with thiopental, sevoflurane and nitrous oxide (group TS, n = 104)
Number of subjects: 211
Study 9785777 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol and fentanyl (group P)
Number of subjects: 211
Study 9785777 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with thiopental, sevoflurane and nitrous oxide (group TS)
Number of subjects: 211
Study 7630982 — intervention group
Group type: EXPERIMENTAL
Intervention: High ability with difficult task standard
Number of subjects: 0
Study 7630982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ability with easy task standard
Number of subjects: 0
Study 7630982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ability with low task standard
Number of subjects: 0
Study 7630982 — intervention group
Group type: EXPERIMENTAL
Intervention: High ability with high task standard
Number of subjects: 0
Study 7630982 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure reactivity
Number of subjects: 0
Study 2715803 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy (CT) - six courses
Number of subjects: 89
Study 2715803 — intervention group
Group type: COMPARATOR
Intervention: Mantle plus lumbar bar radiotherapy (RT) - 36‐45 Gy
Number of subjects: 89
Study 1052105 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (Fasigyn-Pfizer) - 2 grammes as a single oral dose
Number of subjects: 28
Study 1052105 — intervention group
Group type: COMPARATOR
Intervention: Yeast (Placebo)
Number of subjects: 28
Study 31524770 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid-enriched nutrient (12.2 g of branched-chain amino acid, 410 kcal, half consumed as a late evening snack)
Number of subjects: 26
Study 31524770 — intervention group
Group type: COMPARATOR
Intervention: Branched-chain amino acid granules (12 g of branched-chain amino acid)
Number of subjects: 26
Study 30904771 — intervention group
Group type: EXPERIMENTAL
Intervention: Amadeo™ hand training (AHT)
Number of subjects: 50
Study 30904771 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand training (CHT)
Number of subjects: 50
Study 28165578 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on 2.5-mm diameter simulated vessel
Number of subjects: 51
Study 28165578 — intervention group
Group type: COMPARATOR
Intervention: Training on 5-mm diameter simulated vessel
Number of subjects: 51
Study 26964162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation
Number of subjects: 90
Study 26964162 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal acupuncture manipulation plan at the early stage: deep acupuncture and oblique insertion for 20 min with zero-time manipulation
Number of subjects: 90
Study 26964162 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal acupuncture manipulation plan at the later stage: deep acupuncture and oblique insertion for 20 min with three-time manipulation
Number of subjects: 90
Study 24195203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture‐moxibustion group
Number of subjects: 111
Study 24195203 — intervention group
Group type: COMPARATOR
Intervention: Elongated needle group
Number of subjects: 111
Study 24195203 — intervention group
Group type: COMPARATOR
Intervention: Herb‐partitioned moxibustion group
Number of subjects: 111
Study 21288838 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline-containing regimens
Number of subjects: 305
Study 21288838 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-containing regimens
Number of subjects: 305
Study 21288838 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 305
Study 21288838 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 305
Study 19688135 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic transsphenoidal approach
Number of subjects: 50
Study 19688135 — intervention group
Group type: COMPARATOR
Intervention: Sublabial microscopic approach
Number of subjects: 50
Study 19688135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 50
Study 19688135 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher grade of invasiveness
Number of subjects: 50
Study 17015192 — intervention group
Group type: EXPERIMENTAL
Intervention: 'fast track' open verum homeopathy
Number of subjects: 75
Study 17015192 — intervention group
Group type: EXPERIMENTAL
Intervention: 'fast track' double‐blind verum homeopathy
Number of subjects: 75
Study 17015192 — intervention group
Group type: EXPERIMENTAL
Intervention: 'fast track' double‐blind placebo homeopathy
Number of subjects: 75
Study 17015192 — intervention group
Group type: COMPARATOR
Intervention: waiting list control
Number of subjects: 75
Study 15472858 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 649
Study 15472858 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine combined with lamivudine and efavirenz
Number of subjects: 649
Study 12596653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (100 mg twice a day for three consecutive days)
Number of subjects: 0
Study 12596653 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg single dose)
Number of subjects: 0
Study 12596653 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole
Number of subjects: 0
Study 12596653 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 0
Study 9829028 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (selective serotonin reuptake inhibitors)
Number of subjects: 0
Study 9829028 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic augmentations
Number of subjects: 0
Study 9829028 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors
Number of subjects: 0
Study 9829028 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 0
Study 9829028 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgery
Number of subjects: 0
Study 8078530 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg per day for 8 weeks, then 6 mg per day for 2 weeks)
Number of subjects: 176
Study 8078530 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (40 mg per day for 2 weeks, then gradually reduced to 5 mg per day)
Number of subjects: 176
Study 8078530 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 176
Study 8078530 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 176
Study 8078530 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide and Prednisolone
Number of subjects: 176
Study 2635498 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam and Ergotoxin
Number of subjects: 5
Study 829223 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thiotepa chemotherapy after TUR
Number of subjects: 0
Study 829223 — intervention group
Group type: EXPERIMENTAL
Intervention: Local VM 26 chemotherapy after TUR
Number of subjects: 0
Study 829223 — intervention group
Group type: COMPARATOR
Intervention: TUR only
Number of subjects: 0
Study 30779960 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based outpatient palliative care (PC)
Number of subjects: 0
Study 30779960 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29702222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 153
Study 29702222 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 153
Study 27612212 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical vaginal cuff closure technique (group 1)
Number of subjects: 78
Study 27612212 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal vaginal cuff closure technique (group 2)
Number of subjects: 78
Study 27612212 — intervention group
Group type: COMPARATOR
Intervention: Overall results for both groups
Number of subjects: 78
Study 24557812 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional movement circle (FuMoC) training for 12 weeks
Number of subjects: 21
Study 24557812 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 21
Study 21587111 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disc Arthroplasty (TDA)
Number of subjects: 170
Study 21587111 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Fusion (ACDF)
Number of subjects: 170
Study 20056684 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent psychosocial intervention
Number of subjects: 0
Study 17393216 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/day DHA-rich fish oil
Number of subjects: 45
Study 17393216 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day DHA-rich fish oil
Number of subjects: 45
Study 17393216 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (both dosages)
Number of subjects: 45
Study 17393216 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil
Number of subjects: 45
Study 17393216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 45
Study 15731398 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 3 months
Number of subjects: 0
Study 15731398 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after resistance training for 3 months
Number of subjects: 0
Study 12499748 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 45
Study 12499748 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 45
Study 10413345 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI diagnosis of hard disc
Number of subjects: 41
Study 10413345 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI diagnosis of soft disc
Number of subjects: 41
Study 10413345 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in elderly patients
Number of subjects: 41
Study 8534465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 micrograms IV
Number of subjects: 80
Study 8534465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 6 mg IV
Number of subjects: 80
Study 8534465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg IV
Number of subjects: 80
Study 8534465 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 80
Study 2257958 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 132
Study 2257958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 7003457 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg t.i.d. for 3 consecutive days every 2 weeks)
Number of subjects: 24
Study 7003457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7003457 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 24
Study 31698138 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted housing vouchers
Number of subjects: 0
Study 31698138 — intervention group
Group type: COMPARATOR
Intervention: Traditional public housing
Number of subjects: 0
Study 31270173 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB vaccine (Bexsero)
Number of subjects: 120
Study 31270173 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical MenB study (20 adults)
Number of subjects: 120
Study 31270173 — intervention group
Group type: COMPARATOR
Intervention: Other meningococcal vaccines (57 adults)
Number of subjects: 120
Study 28027445 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment coupled with usual lactation consultations
Number of subjects: 97
Study 28027445 — intervention group
Group type: COMPARATOR
Intervention: Usual lactation consultations (Control)
Number of subjects: 97
Study 26391602 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 g/day oral mesalazine
Number of subjects: 112
Study 26391602 — intervention group
Group type: COMPARATOR
Intervention: 2.4 g/day oral mesalazine
Number of subjects: 112
Study 24342265 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Smart program
Number of subjects: 540
Study 24342265 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal lessons)
Number of subjects: 540
Study 23206372 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phase treatment starting in mixed dentition
Number of subjects: 65
Study 23206372 — intervention group
Group type: COMPARATOR
Intervention: One-phase treatment during adolescent dentition
Number of subjects: 65
Study 19237900 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with high internal volume mask (977 mL)
Number of subjects: 14
Study 19237900 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with moderate internal volume mask (84 mL)
Number of subjects: 14
Study 19237900 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with low internal volume mask (163 mL)
Number of subjects: 14
Study 19237900 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with mouthpiece (virtually no internal volume)
Number of subjects: 14
Study 17478385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 0
Study 17478385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 0
Study 17478385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17478385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg and 20 mg
Number of subjects: 0
Study 17478385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 5 mg
Number of subjects: 0
Study 15204222 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntarily admitted patients treated without locking the doors of the wards
Number of subjects: 444
Study 15204222 — intervention group
Group type: COMPARATOR
Intervention: Committed and voluntarily admitted patients
Number of subjects: 444
Study 15204222 — intervention group
Group type: COMPARATOR
Intervention: Patients and relatives
Number of subjects: 444
Study 12217902 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-kDa GH in normal subjects
Number of subjects: 0
Study 12217902 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-kDa GH
Number of subjects: 0
Study 12217902 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin, androgen, and oral estrogen
Number of subjects: 0
Study 12217902 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study 12217902 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant 22-kDa GH
Number of subjects: 0
Study 9524780 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) supplementation (5.2 g daily for 12 weeks)
Number of subjects: 29
Study 9524780 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (olive oil) supplementation (5.2 g daily for 12 weeks)
Number of subjects: 29
Study 9524780 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA content in cell membranes
Number of subjects: 29
Study 9524780 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRV measurement
Number of subjects: 29
Study 7642755 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 16
Study 7642755 — intervention group
Group type: COMPARATOR
Intervention: Control (no relaxation training)
Number of subjects: 16
Study 1519166 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol (220 gm)
Number of subjects: 22
Study 1519166 — intervention group
Group type: COMPARATOR
Intervention: Glucose (320 gm)
Number of subjects: 22
Study 6685641 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior endocrine therapy responders
Number of subjects: 104
Study 6685641 — intervention group
Group type: COMPARATOR
Intervention: Prior endocrine therapy non-responders
Number of subjects: 104
Study 6685641 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders with stable disease
Number of subjects: 104
Study 31474607 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 268
Study 31474607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 268
Study 31474607 — intervention group
Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 268
Study 29179024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (10 min)
Number of subjects: 118
Study 29179024 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (10 min)
Number of subjects: 118
Study 29179024 — intervention group
Group type: COMPARATOR
Intervention: No-instruction control condition
Number of subjects: 118
Study 27492833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 µg twice-daily
Number of subjects: 933
Study 27492833 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/500 µg twice-daily
Number of subjects: 933
Study 24136321 — intervention group
Group type: EXPERIMENTAL
Intervention: Split thickness skin graft (STSG)
Number of subjects: 24
Study 24136321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no STSG)
Number of subjects: 24
Study 24136321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 22521460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 200
Study 22521460 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 200
Study 21338187 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly GCSF therapy before weekly craniospinal radiotherapy
Number of subjects: 40
Study 21338187 — intervention group
Group type: COMPARATOR
Intervention: Control group without GCSF prophylaxis
Number of subjects: 40
Study 17436011 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoscopic splanchnicectomy (VSPL)
Number of subjects: 90
Study 17436011 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptomatic treatment)
Number of subjects: 90
Study 17436011 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with opioids before surgery
Number of subjects: 90
Study 17436011 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 90
Study 16638030 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sterile water injection (0.5 mL)
Number of subjects: 100
Study 16638030 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 100
Study 12785471 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) alone (N=214)
Number of subjects: 431
Study 12785471 — intervention group
Group type: EXPERIMENTAL
Intervention: CBASP in combination with nefazodone (N=217)
Number of subjects: 431
Study 12785471 — intervention group
Group type: COMPARATOR
Intervention: CBASP alone (N=214)
Number of subjects: 431
Study 12785471 — intervention group
Group type: EXPERIMENTAL
Intervention: CBASP (both alone and with medication)
Number of subjects: 431
Study 10958222 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta2-microglobulin levels in patients with HCC
Number of subjects: 120
Study 10958222 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of beta2-microglobulin with interleukin-6 (IL-6)
Number of subjects: 120
Study 10958222 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of beta2-microglobulin with alpha-fetoprotein
Number of subjects: 120
Study 10958222 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of beta2-microglobulin with tumour size
Number of subjects: 120
Study 9008516 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma valproate group (80 to 150 micrograms/mL)
Number of subjects: 143
Study 9008516 — intervention group
Group type: COMPARATOR
Intervention: Low plasma valproate group (25 to 50 micrograms/mL)
Number of subjects: 143
Study 8474315 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 24 IU
Number of subjects: 19
Study 8474315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3089411 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult test offered during a routine consultation
Number of subjects: 25852
Study 3089411 — intervention group
Group type: COMPARATOR
Intervention: Other methods of invitation (letter with test, letter with appointment, educational booklet)
Number of subjects: 25852
Study 3089411 — intervention group
Group type: COMPARATOR
Intervention: Farnborough screening program
Number of subjects: 25852
Study 3089411 — intervention group
Group type: COMPARATOR
Intervention: Screening results
Number of subjects: 25852
Study 29496251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 6717
Study 29496251 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 6717
Study 27189297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg/kg
Number of subjects: 100
Study 27189297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg
Number of subjects: 100
Study 27189297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 100
Study 27189297 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine 1 μg/kg
Number of subjects: 100
Study 27189297 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study 25038306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (LDL-C target <100 mg/dL, switching ART if needed, low-dose aspirin)
Number of subjects: 47
Study 25038306 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (LDL-C target <130 mg/dL)
Number of subjects: 47
Study 23226979 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hyaluronic acid (HA) 200 mg once a day for 12 months
Number of subjects: 60
Study 23226979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19819529 — intervention group
Group type: EXPERIMENTAL
Intervention: JJ-ureteral stent with antireflux-membrane valve
Number of subjects: 133
Study 19819529 — intervention group
Group type: COMPARATOR
Intervention: JJ-ureteral stent without valve
Number of subjects: 133